A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Yuanbin Chen, MD

Phase: III

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07005128

Objective

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival.

Share:

Related Clinical Trials

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
RETROSPECTIVE REVIEW OF PLAVIX RESISTANCE IN CENTRAL FLORIDA PATIENTS UNDERWENT TRANSCAROTID ARTERY REVASCULARIZATION (TCAR)
Are Premature Infants with Bronchopulmonary Dysplasia Requiring Tracheostomy and Ventilation at Increased Risk of Atypical Craniosynostosis?